Posted by Michael Wonder on 11 Aug 2023
US FDA designates PYC's lead as a fast track development program
11 August 2023 - The Company is currently evaluating the safety/tolerability and efficacy of an investigational drug candidate with disease-modifying potential in patients with a blinding eye disease of childhood called retinitis pigmentosa type 11 for which there are no existing treatments.
PYC Therapeutics today announces that the VP-001 program, the first investigational drug candidate designed to address retinitis pigmentosa type 11 to progress to human trials, has received fast track designation from the US FDA.
